NCT01069471已完成1 期
Safety and Reactogenicity of a Candidate Vaccine Against S. Dysenteriae When Administered to Healthy Adults
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Safety and reactogenicity of the bioconjugate vaccine, GVXN SD133
研究概览
简要总结
Healthy volunteers will receive a 2-dose vaccination with Shigella dysenteriae candidate vaccine spaced 8 weeks apart. The objective is to demonstrate the safety and reactogenicity of the Shigella dysenteriae bioconjugate vaccine (GVXN SD133) alone or in combination with an adjuvant (Aluminium Hydroxide). The safety and reactogenicity of the GVXN SD133 vaccine will be also evaluated at two different concentrations of antigen, Shigella polysaccharide O1. Blood samples will be collected at intervals to examine systemic vaccine antigen-specific immune responses.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects of both sexes, aged between 18 and 50 years.
- •Subjects who have undergone a detailed medical history, clinical checkup and are in good health.
- •Subjects who have understood the purpose of the study and have freely signed the informed consent.
- •Subjects who consent with repeated blood samples taking.
- •Subjects who will be available to perform the follow-up visits, are reachable by telephone, and are able to complete the diary cards throughout the study duration.
- •For female volunteers, a negative pregnancy test and an adequate contraception throughout the study duration.
排除标准
- •Known history of recent contact Shigella infection or long-term residence in a Shigella endemic region (Central America, Africa, and India).
- •Known history of hypersensitivity to any component of the vaccine (EPA; Aluminium Hydroxide).
- •Subjects with compromised immune system.
- •Family history of congenital or hereditary immunodeficiency.
- •Chronic administration of an immunosuppressive treatment or other immune-modifying drugs within six months prior to the first vaccine dose.
- •Subjects that received any other vaccine during the 1 month preceding the 1st injection and may receive before the 2nd injection. If the subject needs to be vaccinated during this period, he/she will be withdrawn from the study.
- •Subjects suffering of a disease at the time of enrolment. 'Disease' is defined as the presence of a mild or severe illness with or without fever.
- •Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.
- •Any laboratory data collected during the screening phase found to be outside the normal range defined by the laboratory.
- •Positive test for HIV, and evidence of HBV or HCV.
- •Pregnant or breast-feeding women.
- •History of alcohol, drug or psychotropic drug abuse (which interferes with a normal lifestyle) during the previous year.
- •Subjects for which follow-up is compromised due to socio-cultural, geographic or psychological reasons.
- •Any other significant finding that in the opinion of the Investigator that would increase the risk of having an adverse outcome from participating in the study.
- •Subjects that are participating or have participated in another clinical trial in the last 6 months.
结局指标
主要结局
Safety and reactogenicity of the bioconjugate vaccine, GVXN SD133
时间窗: Each study visits and at the and of the study
次要结局
- Humoral immunogenicity(at day 0, 30, 60, 90 and 150)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in InfantsDiarrhoeaNCT06663436GlaxoSmithKline200
已完成
1 期
A Safety and Immunogenicity Trial in Adults 65 Years of Age or Over to Prevent InfluenzaInfluenzaNCT00706732AlphaVax, Inc.28
招募中
1 期
A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney TransplantHerpes ZosterNCT04006808GlaxoSmithKline184
已完成
1 期
Safety and Immunogenicity of a Group B Streptococcus Vaccine in Non-pregnant Women 18-40 Years of Age.Infection by Streptococcus Group BNCT02459262Minervax ApS240
已完成
1 期
A Study to Assess the Safety, Reactogenicity and Immune Response of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3844766A) in Older AdultsRespiratory Syncytial Virus InfectionsNCT03814590GlaxoSmithKline1,053